Treprostinil: all 100 studies that test it

Page 1 of 1. Open to participants first (13), then studies with results posted, then the rest; newest registration first within each.

• Early Intervention With Inhaled Treprostinil Among Patients With Exercise-Induced Pulmonary Hypertension (EPIH)RecruitingNCT07837830Early Phase 1
• A Study of Inhaled Treprostinil (LIQ861) in Adults With Pulmonary Arterial Hypertension Transitioning From Oral SelexipagRecruitingNCT07759804Phase 4
• A Study of LIQ861 (Inhaled Treprostinil) in Adults With Systemic Sclerosis Who Have Symptomatic Raynaud's Phenomenon AttacksNot yet recruitingNCT07748000Phase 2
• A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILDRecruitingNCT07285655Phase 3
• Efficacy and Safety of Treprostinil in Intermediate-Risk Pulmonary Arterial HypertensionNot yet recruitingNCT07177703Phase 2
• Effects of Inhaled Treprostinil on Exercise Performance in Exercise Induced Pulmonary HypertensionNot yet recruitingNCT07116681Early Phase 1
• Open Label Treprostinil Raynaud's StudyRecruitingNCT07112183Phase 4
• Inhaled Treprostinil (Tyvaso Nebulizer) For COPD Patients With HypoxemiaRecruitingNCT07037836Phase 2
• Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)RecruitingNCT05943535Phase 3
• Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung DiseaseEnrolling by invitationNCT04905693Phase 3
• Trial to Evaluate Parenteral Treprostinil and Riociguat on Right Ventriculo-vascular Coupling and Morphology in Those With Advanced PAHRecruitingNCT04062565Phase 3
• Safety and Efficacy of Treprostinil (Remodulin®) In Reducing Ischemia-Reperfusion Injury During Kidney TransplantationRecruitingNCT04005469Phase 1/2
• Effects of Treprostinil on Right Ventricular Structure and Function in Patients With Pulmonary Arterial HypertensionRecruitingNCT03835676Phase 4
• A Study of Treprostinil to Treat Interstitial Lung Disease Pulmonary HypertensionCompletedNCT05564637Phase 2Results posted
• Multinational Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary FibrosisCompletedNCT05255991Phase 3Results posted
• A Study of Infusion Site Pain After Infusion of Excipients in Participants With Type 1 Diabetes MellitusCompletedNCT05067270Phase 1Results posted
• Open-label, Clinical Study to Evaluate the Safety and Tolerability of TreT in Subjects With PAH Currently Using TyvasoCompletedNCT03950739Phase 1Results posted
• Inhaled Treprostinil in Participants With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)TerminatedNCT03794583Phase 3Results posted
• EXPEDITE: A Study of Remodulin Induction Followed by Orenitram Optimization to Treat Pulmonary Arterial HypertensionCompletedNCT03497689Phase 4Results posted
• A Phase 3 Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Participants With Pulmonary Hypertension (PH) Due to Chronic Obstructive Pulmonary Disease (COPD)TerminatedNCT03496623Phase 3Results posted
• Investigation of the Safety and Pharmacology of Dry Powder Inhalation of TreprostinilCompletedNCT03399604Phase 3Results posted
• TRUST-2: Safety and Efficacy of Intravenous Remodulin® in Patients in India With Pulmonary Arterial Hypertension (PAH)CompletedNCT03055221Phase 4Results posted
• Open-label Extension of Oral Treprostinil in Subjects With PH Associated With HFpEFTerminatedNCT03043651Phase 3Results posted
• Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection FractionTerminatedNCT03037580Phase 3Results posted
• Safety and Tolerability of Rapid Dose Titration of Subcutaneous Remodulin® Therapy in PAH Subjects (RAPID)CompletedNCT02847260Phase 4Results posted
• A Study of Treprostinil and a New Formulation of LY900014 in Healthy Japanese ParticipantsCompletedNCT02770521Phase 1Results posted
• Acute Effects of Inhaled Treprostinil in Fontan PatientsTerminatedNCT02769624Phase 2Results posted
• Safety and Efficacy of Oral Treprostinil in the Treatment of Calcinosis in Patients With Systemic SclerosisCompletedNCT02663895Phase 2Results posted
• An Open Label Extension Study to Evaluate Inhaled Treprostinil in Adult PH With ILD Including CPFETerminatedNCT02633293Phase 2/3Results posted
• Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFECompletedNCT02630316Phase 2/3Results posted
• Perioperative Treprostinil in Pediatric Patients Undergoing the Fontan OperationTerminatedNCT02498444Not applicableResults posted
• Treprostinil Sodium Inhalation for Patients At High Risk for ARDSTerminatedNCT02370095Phase 2Results posted
• Safety, Tolerability, and Pharmacokinetics of Oral Treprostinil in Pediatric PAH Patients Aged 7 to 17 YearsCompletedNCT02276872Phase 2Results posted
• Remodulin as Add-on Therapy for the Treatment of Persistent Pulmonary Hypertension of the NewbornTerminatedNCT02261883Phase 2Results posted
• Pulmonary Rehab in Chronic Obstructive Pulmonary Disease (COPD): Response to TyvasoTerminatedNCT02178566Phase 2Results posted
• A Pharmacokinetic Substudy of the TDE-PH-304 ProtocolCompletedNCT01934582Phase 3Results posted
• Remodulin® to Oral Treprostinil TransitionCompletedNCT01588405Phase 2Results posted
• An Open-Label, Long-Term Study of Oral Treprostinil in Subjects With Pulmonary Arterial HypertensionCompletedNCT01560637Phase 3Results posted
• Phase III Clinical Worsening Study of UT-15C in Subjects With PAH Receiving Background Oral MonotherapyCompletedNCT01560624Phase 3Results posted
• Addition of UT-15C SR to Pulmonary Arterial Hypertension Patients Currently Receiving Tyvaso®CompletedNCT01477333Phase 2Results posted
• Efficacy and Tolerability of Subcutaneously Administered Treprostinil Sodium in Patients With Severe (Non-operable) Chronic Thromboembolic Pulmonary Hypertension (CTREPH)CompletedNCT01416636Phase 3Results posted
• A 48-week Study of the Effect of Dual Therapy (Inhaled Treprostinil and Tadafafil) Versus Monotherapy (Tadalafil).CompletedNCT01305252Phase 4Results posted
• Transition From Injectable Prostacyclin Medication to Inhaled Prostacyclin MedicationCompletedNCT01268553Phase 4Results posted
• A Dose Response Study of UT-15C SR in Patients With Exercise-Induced Pulmonary HypertensionCompletedNCT01104870Phase 2Results posted
• An Open-Label Extension Trial of UT-15C Sustained-release (SR) in Subjects With Pulmonary Arterial HypertensionCompletedNCT01027949Phase 3Results posted
• Efficacy and Safety of Oral UT-15C Tablets to Treat Pulmonary Arterial HypertensionCompletedNCT00887978Phase 3Results posted
• Open-Label Study of Oral Treprostinil in Digital UlcersTerminatedNCT00848107Phase 2Results posted
• Digital Ischemic Lesions in Scleroderma Treated With Oral Treprostinil DiethanolamineCompletedNCT00775463Phase 2Results posted
• Safety Evaluation of Inhaled Treprostinil Administration Following Transition From Inhaled Ventavis in Pulmonary Arterial Hypertension (PAH) SubjectsCompletedNCT00741819Phase 4Results posted
• Treprostinil Therapy For Patients With Interstitial Lung Disease And Severe Pulmonary Arterial HypertensionCompletedNCT00705133Phase 2Results posted
• Rapid Switch From Flolan to Remodulin in the Outpatient ClinicTerminatedNCT00643604Phase 4Results posted
• Safety, Efficacy, and Treatment Satisfaction Switching From Flolan to Remodulin Using the Crono Five Ambulatory Pump in Patients With PAHTerminatedNCT00439946Phase 4Results posted
• Safety, Efficacy and Treatment Satisfaction in Patients With PAH Rapidly Switched From Epoprostenol to RemodulinCompletedNCT00373360Phase 4Results posted
• FREEDOM-C: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor for the Treatment of Pulmonary Arterial Hypertension (PAH)CompletedNCT00325442Phase 3Results posted
• FREEDOM - M: Oral Treprostinil as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH)CompletedNCT00325403Phase 3Results posted
• Clinical Investigation Into Inhaled Treprostinil Sodium in Patients With Severe Pulmonary Arterial Hypertension (PAH)CompletedNCT00147199Phase 3Results posted
• Subcutaneous Treprostinil as a Bridge to Lung Transplantation in Severe Pulmonary Hypertension: A Single-Arm Retrospective StudyCompletedNCT06605326Phase 4
• A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of C16TR for Inhalation With Tyvaso® Cohort in Healthy ParticipantsCompletedNCT06193031Phase 1
• A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial HypertensionActive, not recruitingNCT05203510Phase 4
• Telemonitoring to Treat Group 2 Pulmonary HypertensionWithdrawnNCT04882774Phase 2
• Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary FibrosisCompletedNCT04708782Phase 3
• Effect of BIA 5-1058 on the Steady State Pharmacokinetics of TreprostinilCompletedNCT04675944Phase 1
• Extension Study for Participants in LIQ861 Trials to Evaluate the Long-term Safety of Dry Powder Inhalation of TreprostinilActive, not recruitingNCT03992755Phase 3
• Hemodynamic Evaluation of Dose-response and Safety of Dry Powder Inhalation of TreprostinilTerminatedNCT03884465Phase 2
• Inhaled Treprostinil in Sarcoidosis Patients With Pulmonary HypertensionCompletedNCT03814317Phase 2
• Pharmacokinetics, Safety and Tolerability of Treprostinil Inhalation Powder in Healthy Normal VolunteersCompletedNCT03464864Phase 1
• Study to Evaluate Efficacy and Safety of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Sickle Cell Disease (SCD)WithdrawnNCT03055234Phase 3
• Safety of Transition From Selexipag to Remodulin® Then Oral Treprostinil in Symptomatic Adult PAHWithdrawnNCT03016468Phase 2
• Safety and Tolerability of Inhaled Treprostinil in Adult PH Due to COPDWithdrawnNCT03012646Phase 2
• Study to Compare Triple Therapy (Oral Treprostinil, Ambrisentan, and Tadalafil) With Dual Therapy (Ambrisentan, Tadalafil, and Placebo) in Subjects With Pulmonary Arterial HypertensionWithdrawnNCT02999906Phase 3
• Safety, Tolerability, Pharmacokinetics and Efficacy of Two Different Rates of Subcutanous Remodulin® Dose Titration in Pulmonary Arterial HypertensionWithdrawnNCT02893995Phase 4
• An Open Label Extension Study to Evaluate the Safety of Continued Therapy of Subcutanous Remodulin® in Pulmonary Arterial HypertensionWithdrawnNCT02882126Phase 4
• Study of Remodulin® in Pediatric Pulmonary Hypertension With Single Ventricular Physiology After Fontan SurgeryCompletedNCT02865733Phase 3
• Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary FibrosisWithdrawnNCT02603068Phase 2
• Assess Efficacy of of Oral Treprostinil in Patients With Symptomatic Primary or Secondary Raynaud's PhenomenonCompletedNCT02583789Early Phase 1
• Pharmacokinetic Interaction of Oral Treprostinil and Ethanol in Healthy VolunteersCompletedNCT02318758Phase 1
• Efficacy of Remodulin in Adults With Congenital Heart Disease (ACHD) and Pulmonary HypertensionWithdrawnNCT01980979Not applicable
• Safety and Efficacy of Perioperative Remodulin® in Orthotopic Liver Transplant RecipientsWithdrawnNCT01884038Phase 2/3
• Treatment of Pulmonary Hypertension Associated COPD With Inhaled Treprostinil-1CompletedNCT01758744Phase 1
• Three Times Daily Dosing of UT-15CCompletedNCT01746485Phase 1
• Inhaled Treprostinil for PAH: Open-label ExtensionWithdrawnNCT01557660Phase 3
• Safety and Efficacy of Inhaled Treprostinil in Patients With PAHWithdrawnNCT01557647Phase 3
• Safety and Efficacy of Treprostinil in Ischemia and Reperfusion Injury in Adult Orthotopic Liver TransplantationCompletedNCT01481974Phase 1
• A Bioavailability Study Comparing Treprostinil Diethanolamine Oral Tablets and Oral Solution in Healthy VolunteersCompletedNCT01172496Phase 1
• Comparative Bioavailability of Treprostinil Diethanolamine Manufactured by Two Independent FacilitiesCompletedNCT01165476Phase 1
• Pharmacokinetic Linearity and Comparative Bioavailability of Treprostinil DiethanolamineCompletedNCT01153386Phase 1
• The Effect of Renal Impairment on the Pharmacokinetics of Oral TreprostinilCompletedNCT01131845Phase 1
• Cutaneous Iontophoresis of Iloprost and Treprostinil in Healthy VolunteersCompletedNCT01082484Phase 1/2
• Effect of Esomeprazole on the Pharmacokinetics of Oral TreprostinilCompletedNCT00963027Phase 1
• Effect of Food on the Pharmacokinetics of Oral TreprostinilCompletedNCT00963001Phase 1
• Pharmacokinetics of Oral Treprostinil in Patients With Systemic SclerosisCompletedNCT00848939Phase 1
• FREEDOM DR: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor or as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH)WithdrawnNCT00760916Phase 3
• Safety Study of UT-15C SR (Oral Treprostinil) in Patients Undergoing a Lower Limb Endovascular ProcedureCompletedNCT00651885Phase 2
• Study of Intravenous Remodulin in Patients in India With Pulmonary Arterial HypertensionTerminatedNCT00494533Phase 4
• Transitioning To IV Remodulin From Ventavis in Patients With PAH: Safety, Efficacy and Treatment SatisfactionTerminatedNCT00458042Phase 4
• UT-15C SR in the Treatment of Critical Limb IschemiaStatus unknownNCT00445159Phase 2
• Effects of Remodulin in Patients With Critical Limb Ischemia Following a Vein Bypass GraftTerminatedNCT00067041Phase 2/3
• Study of Remodulin in Patients With Critical Limb Ischemia With No Planned Revascularization ProceduresTerminatedNCT00060996Phase 3
• A Transition Study From Flolan® to Remodulin® in Patients With Pulmonary Arterial HypertensionCompletedNCT00058929Phase 4
• Phase III Randomized Study of UT-15 in Patients With Primary Pulmonary HypertensionCompletedNCT00004497Phase 3

← Treprostinil overview